Vicarious Surgical, Inc. · OTC:RBOT

Vicarious Surgical — Investor Presentation (July 2023)

22 slides from Vicarious Surgical's investor presentation, Jul 27, 2023

  1. Slide 1: Investor Presentation July 2023

    INVESTOR PRESENTATION JULY 2023

  2. Slide 2: Disclaimer

    DISCLAIMER VICARIOUS SURGICAL INVESTOR PRESENTATION JULY 2023 00 | SUMMARY 2 This presentation includes “forward - looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The company’s actual results may differ fro

  3. Slide 3: Key Investment Highlights

    KEY INVESTMENT HIGHLIGHTS 1 VICARIOUS SURGICAL ESTIMATES FROM DATA SOURCED FROM LSI MARKET SIZE ANALYSIS 2022 DATA AND PUBLIC FILINGS. ASSUMES $3,319 REVENUE PER PROCEDURE CURRENTLY REALIZED BY LEGACY ROBOTIC COMPANY. 2 PARTNERSHIPS FOR PURPOSE OF DEVELOPMENT, VERIFICATION AND VALIDATION, CLINICAL T

  4. Slide 4: Surgery Today

    SURGERY TODAY 00 | SUMMARY 4 1 VICARIOUS SURGICAL ESTIMATES FROM DATA SOURCED FROM LSI MARKET SIZE ANALYSIS 2022 DATA AND PUBLIC FILINGS. ASSUMES $3,319 REVENUE PER PROCEDURE CURRENTLY REALIZED BY LEGACY ROBOTIC COMPANY. 2 VICARIOUS SURGICAL ESTIMATES FROM LSI MARKET DATA. 2022 DATA 3 DHARAP SB, BAR

  5. Slide 5: The Vicarious Surgical System

    VICARIOUS SURGICAL INVESTOR PRESENTATION JULY 2023 5 THE VICARIOUS SURGICAL SYSTEM 01

  6. Slide 6: The System

    THE SYSTEM [1] VICARIOUS SURGICAL SYSTEM IS CAPABLE OF TROCAR SIZES AS LOW AS 1.2CM. CURRENT DISPOSABLES REQUIRE 1.8 CM TROCAR. [2] INCLUDES ADDITIONAL FEATURES EXPECTED AFTER INITIAL LAUNCH AND NECESSARY REGULATORY APPROVAL OF THESE FEATURES. OUR DECOUPLED TECHNOLOGY UNIQUELY BENEFITS THE PATIENT,

  7. Slide 7: Decoupled Actuators: Our Enabling Technology

    DECOUPLED ACTUATORS: OUR ENABLING TECHNOLOGY PROPRIETARY TECHNOLOGY: • ISOLATES CABLE PATHWAYS • REMOVES BUILD UP OF FORCE BETWEEN JOINTS 1 UNWANTED FORCE BUILD - UP 1x 50x 20x 2 3 4 5 6 7 8 9 40x 30x 10x EXISTING SURGICAL ROBOTS IF THEY HAD 5+ DEGREES OF FREEDOM IN THE BODY CABLE BREAKING POINT 1 E

  8. Slide 8: One Small Incision

    ONE SMALL INCISION MINIMIZING PATIENT COMPLICATIONS THROUGH 1.8CM TROCAR 1 1.8cm INCISION SIZE INCISIONAL COMPLICATION R ATE 20% 10% OBTURATOR UTILIZATION SCALPEL UTILIZATION • <2.0CM INCISION ABILITY TO UTILIZE OBTURATOR • >2.0CM INCISION REQUIRES SCALPEL • OBTURATOR DRIVES COMPLICATION RATES DOWN

  9. Slide 9: Unrestricted Surgeon Workspace

    01 | THE VICARIOUS SURGICAL SYSTEM UNRESTRICTED SURGEON WORKSPACE NEARLY 360 ƒ WORKSPACE IN THE ABDOMEN THROUGH ONE 1.8CM 1 TROCAR THE 13 DEGREES OF FREEDOM POWERED BY PROPRIETARY DECOUPLED MOTION PROVIDES SURGEONS UNPRECEDENTED DEXTERITY AND RANGE OF MOTION [1] VICARIOUS SURGICAL SYSTEM IS CAPABLE

  10. Slide 10: Sensing and Visualization

    SENSING AND VISUALIZATION COLLECTING HIGH QUALITY DATA: THE KEY TO ENABLE SURGEON DECISION SUPPORT, MACHINE LEARNING, AND BROADER AI CAPABILITY 1 01 | THE VICARIOUS SURGICAL SYSTEM 10 MEASUREMENT OF FORCE AND POSITION WITH SENSORS FROM WITHIN ABDOMINAL CAVITY DECOUPLED ACTUATORS ENABLE UNPRECEDENTED

  11. Slide 11: Attractive Cost Model

    11 01 | THE VICARIOUS SURGICAL SYSTEM A TT R A C TI V E COST MODEL • Capital equipment is primarily non - robotic as movement is generated from within the abdomen • Cost of goods of capital equipment is expected to be significantly lower than competing products 1 • Decoupled actuators enable high fo

  12. Slide 12: Future of Surgery

    VICARIOUS SURGICAL INVESTOR PRESENTATION JULY 2023 12 FUTURE OF SURGERY 02

  13. Slide 13: Transforming Robotics to Become the Standard of Care

    TRANSFORMING ROBOTICS TO BECOME THE STANDARD OF CARE 1 DHARAP SB, BARBANIYA P, NAVGALE S. INCIDENCE AND RISK FACTORS OF POSTOPERATIVE COMPLICATIONS IN GENERAL SURGERY PATIENTS. CUREUS. 2022 NOV 1;14(11):E30975. DOI: 10.7759/CUREUS.30975. PMID: 36465229; PMCID: PMC9714582. 2 INCLUDES ADDITIONAL FEATU

  14. Slide 14: Pioneering Automated Patient Protection to Generate Improved Patient Outcomes

    PIONEERING AUTOMATED PATIENT PROTECTION 1 TO GENERATE IMPROVED PATIENT OUTCOMES BUILDING T O W ARD S PROCEDU R A L AUTOMATION PROCEDURAL AUTOMATION Our platform is uniquely engineered to deliver reliable, repeatable results through future “autopilot” automation UNIQUE SYSTEM ARCHITECTURE Decoupled a

  15. Slide 15: Pathway to Commercialization

    VICARIOUS SURGICAL INVESTOR PRESENTATION JULY 2023 15 P A TH W A Y TO COMMERCIALIZ A TION 03

  16. Slide 16: Pathway to Commercialization: Hospital System Partners

    03 | PATHWAY TO COMMERCIALIZATION HOSPITAL SYSTEM PARTNERS 16 KEY PARTNERSHIPS WITH THREE LEADING HEALTHCARE PROVIDERS REPRESENTING OVER 200 HOSPITALS AND 150 SURGERY CENTERS CREATING THE FOUNDATION FOR A STRONG COMMERICAL LAUNCH CLINICAL EXECUTION Joint site selection and clinical trial support for

  17. Slide 17: Addressable Procedures and Target Launch Indication

    1 COLORECTAL, SMALL BOWEL, BARIATRIC, ESOPHAGEAL, BARIATRIC, STOMACH (NON - ENDOSCOPIC), LSI WW 2022 DATA 2 VICARIOUS SURGICAL ESTIMATES FROM LSI WW 2022 DATA, INCLUDES SOME PATIENTS WHO CHOSE TO NOT HAVE HERNIAS REPAIRED WITH LEGACY TECHNIQUES 3 LSI WW 2022 DATA 4 HYSTERECTOMY, OOPHORECTOMY, COLPOP

  18. Slide 18: Executing on Our Roadmap

    2025 EXECUTING ON OUR ROADMAP 2023 2024 NOTE: ACTUAL MILESTONES AND TIMELINE MAY VARY AS CERTAIN ACTIVITIES ARE BEYOND VICARIOUS SURGICAL’S CONTROL Version 1.0 Build Integrated FDA De Novo Submission First Clinical Patient 2022 Beta 2 Design Lock Version 1.0 Design Lock HCA & UH Centers of Excellenc

  19. Slide 19: Team and Investors

    TEAM AND INVESTORS 04 VICARIOUS SURGICAL INVESTOR PRESENTATION JULY 2023 19

  20. Slide 20: Experienced Management Team

    EXPERIENCED MANAGEMENT TEAM GENERAL COUNSEL AND CHIEF LEGAL OFFICER JUNE MORRIS VP OF PRODUCT DESIGN AND COMMERCIALIZATION MICHAEL PRATT CHIEF FINANCIAL OFFICER BILL KELLY CO - FOUNDER, CHIEF TECHNOLOGY OFFICER SAMMY KHALIFA CO - FOUNDER, CHIEF EXECUTIVE OFFICER ADAM SACHS CHIEF OPERATING OFFICER JO

  21. Slide 21: Experienced Board and Advisors

    EXPERIENCED BOARD AND ADVISORS SEASONED INVESTORS Bill Gates EXECUTIVE CHAIRMAN DAVID STYKA BOARD DIRECTOR DAVID HO BOARD DIRECTOR SAMMY KHALIFA BOARD DIRECTOR ADAM SACHS BOARD DIRECTOR BEVERLY HUSS VICARIOUS SURGICAL INVESTOR PRESENTATION JULY 2023 04 | OUR TEAM AND INVESTORS 21 BOARD DIRECTOR DONA

  22. Slide 22: Thank You

    VICARIOUS SURGICAL INVESTOR PRESENTATION JULY 2023 THANK YOU 78 Fourth Avenue Waltham, MA, 02451 vicarioussurgical.com +1.617.868.1700 VICARIOUS SURGICAL 22

Vicarious Surgical — Investor Presentation (July 2023) on 6ix